Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Ilya Rachman
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Beta
- 0.11
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 30.83
Financials
Net Income
$-11.56MEBITDA
$-11.54MFree Cash Flow
$-11.76MEPS (diluted)
$-0.18Shares Outstanding (diluted)
63.77M+1789.5%Operating Expenses
$12.46MCash & Debt
$232.11MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-29.44M | $-0.89 |
| 2024 | $0.00 | $-21.61M | $-0.76 |
| 2023 | $0.00 | $-15.43M | $-0.89 |
| 2022 | $0.00 | $-8.23M | $-0.59 |
| 2021 | $0.00 | $-24.38M | $-6.64 |
| 2020 | $0.00 | $-1.15M | $-0.15 |
| 2019 | $0.00 | $-972.8K | $-0.29 |
Valuation
IMMXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-80.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·5d ago·Negative
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share.
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript
View source ↗ - Newsglobenewswire.com·7d ago·Negative
… of $125 Million Underwritten Offering of Common Stock LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and …
View source ↗
Earnings
Fri, Nov 6(in 4 weeks)
Consensus estimate $-0.19 per share
Typical surprise -4.8% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 7$-0.18 vs $-0.17miss
- Thu, May 7$-0.18 vs $-0.21beat
- Wed, Mar 25$-0.27 vs $-0.21miss
- Fri, Nov 7$-0.24 vs $-0.19miss
- Fri, Aug 8$-0.22 vs $-0.21miss
- Thu, May 8$-0.15 vs $-0.23beat
Estimates and results for IMMX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by IMMX officers and directors.
- Bought
- $922k
- Sold
- —
33 trades
0 trades
- Rachman Ilya Mbought
- Morris Gabriel Sbought
- Rachman Ilya Mbought
- Morris Gabriel Sbought
- Rachman Ilya Mbought
- Morris Gabriel Sbought
- Hsu Jasonbought
- Hsu Jasonbought
67 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in IMMX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.